Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-559 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TAK-559 16 mg QD | EXPERIMENTAL | - |
| TAK-559 32mg QD | EXPERIMENTAL | - |
| Placebo QD | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TAK-559 | DRUG | TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks. |
| Placebo | DRUG | TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks. |
Inclusion Criteria: * Is diagnosed with type 2 diabetes mellitus using American Diabetes Association diagnostic criteria, and on a stable dose of an oral anti-diabetic monotherapy prior to Screening A. * Had a glycosylated hemoglobin level greater than or equal to 8.0% and less than or equal to 10....
TAK-559 is an investigational small molecule being developed for the treatment of Diabetes Mellitus, specifically type 2 diabetes. It is intended to help manage blood sugar levels in patients with this condition. The drug is currently in Phase 3 clinical development, meaning it is still being studied and has not yet been approved for commercial use.
TAK-559 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Takeda is listed on the stock exchange under the ticker symbol TAK. The company is conducting clinical trials to evaluate the safety and efficacy of TAK-559 in patients with type 2 diabetes.
TAK-559 is in Phase 3 clinical development. This is the final stage of testing before a potential regulatory submission. The drug is being studied in a randomized, double-blind, placebo-controlled trial to assess its efficacy in treating subjects with type 2 diabetes mellitus. It is not yet approved by regulatory authorities.
TAK-559 has one completed Phase 3 clinical trial registered under NCT00763022, titled "Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus." This trial enrolled 302 participants aged 25 years and older, with no healthy volunteers included. The study was randomized, double-blind, and placebo-controlled.
TAK-559 is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of type 2 diabetes mellitus. The completed Phase 3 trial (NCT00763022) evaluated its efficacy, but the drug has not yet received regulatory approval and remains under investigation.